Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William L Redmond

Showing results (41-50 of 63) with videos related to

Pageof 7
Sort By:
Plos One|August 13, 2013
The peripheral myeloid expansion driven by murine cancer progression is reversed by radiation therapy of the tumorMarka R Crittenden, Talicia Savage, Benjamin Cottam, et al.
Frontiers in Oncology|June 25, 2021
A Case Series of Metastatic Metaplastic Breast Carcinoma Treated With Anti-PD-1 TherapyIsaac Kim, Venkatesh Rajamanickam, Brady Bernard, et al.
Journal for Immunotherapy of Cancer|May 28, 2020
NKTR-214 immunotherapy synergizes with radiotherapy to stimulate systemic CD8<sup>+</sup> T cell responses capable of curing multi-focal cancerJoshua M Walker, Annah S Rolig, Deborah H Charych, et al.
Oncoimmunology|May 13, 2026
Novel multiplex immunofluorescence-based tumor inflammation score provides apparent predictive biomarker in a phase I/II study of pembrolizumab with gemcitabine in patients with previously-treated advanced non-small cell lung cancer (NSCLC)Rachel E Sanborn, Shawn M Jensen, Christopher Paustian, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 16, 2010
Adjuvant therapy with agonistic antibodies to CD134 (OX40) increases local control after surgical or radiation therapy of cancer in miceMichael J Gough, Marka R Crittenden, MaryClare Sarff, et al.
Oncotarget|July 19, 2016
Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancerJulie N Graff, Joshi J Alumkal, Charles G Drake, et al.
Breast Cancer Research : BCR|January 8, 2021
Multiplex immunofluorescence to measure dynamic changes in tumor-infiltrating lymphocytes and PD-L1 in early-stage breast cancerKatherine Sanchez, Isaac Kim, Brie Chun, et al.
Journal for Immunotherapy of Cancer|May 22, 2025
INBRX-106: a hexavalent OX40 agonist that drives superior antitumor responses via optimized receptor clusteringNisha Holay, Rashi Yadav, Sae Jeong Ahn, et al.
Molecular Cancer Research : MCR|March 18, 2022
Intratumoral Electroporation of Plasmid Encoded IL12 and Membrane-Anchored Anti-CD3 Increases Systemic Tumor ImmunityMia Han, Bianca Nguyen, Jack Y Lee, et al.
Journal for Immunotherapy of Cancer|July 4, 2020
A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide aloneJulie N Graff, Tomasz M Beer, Joshi J Alumkal, et al.
Pageof 7

Showing results (41-50 of 63) with videos related to

Sort By:
Pageof 7
Plos One|August 13, 2013
The peripheral myeloid expansion driven by murine cancer progression is reversed by radiation therapy of the tumorMarka R Crittenden, Talicia Savage, Benjamin Cottam, et al.
Frontiers in Oncology|June 25, 2021
A Case Series of Metastatic Metaplastic Breast Carcinoma Treated With Anti-PD-1 TherapyIsaac Kim, Venkatesh Rajamanickam, Brady Bernard, et al.
Journal for Immunotherapy of Cancer|May 28, 2020
NKTR-214 immunotherapy synergizes with radiotherapy to stimulate systemic CD8<sup>+</sup> T cell responses capable of curing multi-focal cancerJoshua M Walker, Annah S Rolig, Deborah H Charych, et al.
Oncoimmunology|May 13, 2026
Novel multiplex immunofluorescence-based tumor inflammation score provides apparent predictive biomarker in a phase I/II study of pembrolizumab with gemcitabine in patients with previously-treated advanced non-small cell lung cancer (NSCLC)Rachel E Sanborn, Shawn M Jensen, Christopher Paustian, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 16, 2010
Adjuvant therapy with agonistic antibodies to CD134 (OX40) increases local control after surgical or radiation therapy of cancer in miceMichael J Gough, Marka R Crittenden, MaryClare Sarff, et al.
Oncotarget|July 19, 2016
Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancerJulie N Graff, Joshi J Alumkal, Charles G Drake, et al.
Breast Cancer Research : BCR|January 8, 2021
Multiplex immunofluorescence to measure dynamic changes in tumor-infiltrating lymphocytes and PD-L1 in early-stage breast cancerKatherine Sanchez, Isaac Kim, Brie Chun, et al.
Journal for Immunotherapy of Cancer|May 22, 2025
INBRX-106: a hexavalent OX40 agonist that drives superior antitumor responses via optimized receptor clusteringNisha Holay, Rashi Yadav, Sae Jeong Ahn, et al.
Molecular Cancer Research : MCR|March 18, 2022
Intratumoral Electroporation of Plasmid Encoded IL12 and Membrane-Anchored Anti-CD3 Increases Systemic Tumor ImmunityMia Han, Bianca Nguyen, Jack Y Lee, et al.
Journal for Immunotherapy of Cancer|July 4, 2020
A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide aloneJulie N Graff, Tomasz M Beer, Joshi J Alumkal, et al.
Pageof 7